Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized PatientsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study asked whether SARS-CoV-2 specifically reshapes the upper-airway bacterial community, or whether respiratory illness in general does. Researchers profiled the naso-oropharyngeal microbiota using 16S rRNA gene V3-V4 amplicon sequencing. The key design feature was a disease control group. Most prior work compared COVID-19 patients only to healthy people. Here a non-COVID respiratory patient group let the team separate the virus effect from the illness effect. Differential abundance, alpha and beta diversity, and PICRUSt2-predicted metabolism were compared across the three groups.
Who was studied?
The cohort was 221 people in Hong Kong: 76 hospitalized COVID-19 patients, 69 hospitalized non-COVID-19 patients with respiratory symptoms or related illness, and 76 local community controls. Samples were pooled nasopharyngeal and throat swabs. No subject had received antimicrobial therapy within two weeks before collection. COVID patients had a median age of 35 years. Half had no pneumonia, 32 had moderate disease, and only 6 had severe or critical disease. Non-COVID patients were older (median 73 years).
What were the most important findings?
Both hospitalized groups differed clearly from community controls but not from each other. Bacteroidota was enriched and Proteobacteria reduced in both patient groups (p less than 0.0001), and richness and Shannon diversity fell similarly. Beta diversity by weighted UniFrac did not separate COVID from non-COVID patients (p greater than 0.05). Nine genera were enriched in COVID patients versus controls, but six were also enriched in non-COVID patients. Only two genera were uniquely enriched in COVID patients. One uniquely enriched genus correlated positively with C-reactive protein (Spearman rho 0.4, p less than 0.01).
What are the greatest implications of this study?
The results suggest respiratory disease, not SARS-CoV-2 specifically, drives most upper-airway dysbiosis. Studies lacking a disease control group may overstate a COVID-specific microbiome signature. A small set of bacteria was enriched in COVID patients but not in other respiratory patients. These taxa may be more specific candidate biomarkers for SARS-CoV-2 detection. Because 16S sequencing cannot resolve virulence factors, and severe cases were few, these associations do not establish causation and need metagenomic follow-up.